Simulations Plus (NASDAQ:SLP) Coverage Initiated by Analysts at Stephens

Stephens assumed coverage on shares of Simulations Plus (NASDAQ:SLP) in a report issued on Friday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $39.00 target price on the technology company’s stock.

Several other equities research analysts have also weighed in on SLP. William Blair reissued an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, November 6th. KeyCorp started coverage on Simulations Plus in a research report on Monday, July 29th. They issued an “overweight” rating and a $47.00 price target for the company. BTIG Research reduced their price objective on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. Finally, StockNews.com cut shares of Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $51.40.

Simulations Plus Stock Down 3.2 %

Shares of Simulations Plus stock opened at $28.77 on Friday. The business has a fifty day simple moving average of $31.19 and a 200-day simple moving average of $38.88. The firm has a market cap of $577.41 million, a price-to-earnings ratio of 58.72 and a beta of 0.71. Simulations Plus has a fifty-two week low of $27.22 and a fifty-two week high of $51.22.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings data on Wednesday, October 23rd. The technology company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The company had revenue of $18.70 million during the quarter, compared to analyst estimates of $19.73 million. During the same quarter last year, the firm posted $0.18 EPS. The business’s revenue for the quarter was up 19.9% on a year-over-year basis. Analysts anticipate that Simulations Plus will post 1.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $31.26, for a total value of $625,200.00. Following the transaction, the director now owns 3,481,592 shares in the company, valued at approximately $108,834,565.92. This represents a 0.57 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 60,750 shares of company stock valued at $1,905,655. Corporate insiders own 20.90% of the company’s stock.

Hedge Funds Weigh In On Simulations Plus

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SLP. Public Employees Retirement System of Ohio acquired a new position in shares of Simulations Plus during the 1st quarter worth $1,082,000. Silvercrest Asset Management Group LLC bought a new stake in Simulations Plus in the first quarter worth $4,717,000. Deerfield Management Company L.P. Series C bought a new stake in Simulations Plus in the second quarter worth $811,000. Allspring Global Investments Holdings LLC acquired a new position in Simulations Plus during the first quarter worth $70,000. Finally, US Bancorp DE raised its holdings in Simulations Plus by 37.0% during the third quarter. US Bancorp DE now owns 4,974 shares of the technology company’s stock valued at $159,000 after buying an additional 1,343 shares in the last quarter. Institutional investors own 78.08% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.